Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-122M | $-3M | $-116M | 2.8% | - | -97.9% |
| 2024 | $0M | $-155M | $-157M | $-149M | 85.9% | - | 33.1% |
| 2023 | $0M | $-143M | $-118M | $74M | 471.6% | - | -348.5% |
| 2022 | $0M | $-158M | $47M | $-87M | 55.3% | - | - |
| 2021 | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Cost Of Revenue | - |
| Gross Profit | - |
| Operating Expense | 122.80 |
| Research And Development | 81.30 |
| Selling General And Administration | 41.50 |
| Total Expenses | 122.80 |
| Operating Income | -122.80 |
| Total Operating Income As Reported | -122.80 |
| EBITDA | -121.83 |
| Normalized EBITDA | -236.78 |
| EBIT | -122.80 |
| Interest Income | 5.06 |
| Interest Expense | - |
| Net Interest Income | 5.06 |
| Other Non Operating Income Expenses | - |
| Other Income Expense | 114.94 |
| Interest Income Non Operating | 5.06 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 5.06 |
| Pretax Income | -2.80 |
| Tax Provision | 2.01 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 24.14 |
| Net Income Continuous Operations | -4.81 |
| Net Income From Continuing And Discontinued Operation | -3.35 |
| Net Income From Continuing Operation Net Minority Interest | -4.81 |
| Net Income | -3.35 |
| Net Income Common Stockholders | -3.35 |
| Net Income Including Noncontrolling Interests | -3.35 |
| Normalized Income | -95.61 |
| Diluted NI Availto Com Stockholders | -3.35 |
| Basic Average Shares | 63.51 |
| Diluted Average Shares | 63.51 |
| Reconciled Depreciation | 0.96 |
| Reconciled Cost Of Revenue | - |
| Total Unusual Items | 114.94 |
| Total Unusual Items Excluding Goodwill | 114.94 |
| Net Income Discontinuous Operations | 1.46 |
| Special Income Charges | 251.66 |
| Gain On Sale Of Business | 237.59 |
| Other Special Charges | -14.07 |
| Gain On Sale Of Security | -136.72 |
| General And Administrative Expense | 41.50 |
| Other Gand A | 36.84 |
| Salaries And Wages | 4.66 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Omeros Corporationthis co. | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| Geron Corporation | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| BioAge Labs, Inc. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| HealthStream, Inc. | HSTM | $739M | 40.28 |
| - |
| - |
| - |
| 2.09 |
| 5.2% |
| 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M | -153.68 | 1.32 | -0.9% | 20.09 |
| Peer Median | - | -10.10 | 3.53 | -31.6% | -8.01 | |